K

Karyopharm Therapeutics
D

KPTI

0.67170
USD
-0.01
(-1.60%)
مغلق
حجم التداول
26,596
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
84,762,323
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ABBV
    ABBV
    -3.460
    (-2.00%)
    169.130 USD
    BMY
    BMY
    0.025
    (0.04%)
    57.075 USD
    GILD
    GILD
    0.070
    (0.08%)
    93.020 USD
    JNJ
    JNJ
    -2.915
    (-1.97%)
    145.250 USD
    MRK
    MRK
    -0.560
    (-0.58%)
    95.670 USD
    NVS
    NVS
    -1.600
    (-1.60%)
    98.180 USD
    PFE
    PFE
    -0.621
    (-2.33%)
    26.015 USD
    المزيد
الأخبار
المقالات

العنوان: Karyopharm Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuselarge B-cell lymphoma. The company derives its revenue from United States.